

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number

10/623,464

Filing Date

July 18, 2003

First Named Inventor

Deh-Ming Chang

Group Art Unit

1645

Examiner Name

Unassigned

Total Number of Pages in This Submission

Attorney Docket Number

411-000100US

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
☐ Fee Attached
- ☐ Amendment / Response
☐ After Final
☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/
Incomplete Application
- ☐ Response to Missing
Parts under 37 CFR
1.52 or 1.53

- ☐ Assignment Papers
(for an Application)
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition Routing Slip (PTO/SB/69)
and Accompanying Petition
- ☐ Petition to Convert to a
Provisional Application
- ☐ Power of Attorney, Revocation
Change of Correspondence
Address
- ☐ Terminal Disclaimer
- ☐ Small Entity Statement
- ☐ Request for Refund

- ☐ After Allowance Communication
to Group
- ☐ Appeal Communication to Board
of Appeals and Interferences
- ☐ Appeal Communication to Group
(Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Additional Enclosure(s)
(please identify below):

USPTO Form 1449; Cited
References (50); receipt
acknowledgment postcard**Authorization to Charge Deposit Account**Please charge Deposit Account No. 50-0893 for any additional fees associated with
this paper or during the pendency of this application, including any extensions of time
for consideration of the documents enclosed.

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENTFirm
or
Individual name

Paul Littlepage, Reg. No. 48,581, Quine Intellectual Property Law Group, P.C.

Signature

Date

March 31, 2004

CERTIFICATE OF MAILINGI hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient
postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name

Amelia Weintraub

Signature

Date


March 31, 2004



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313-1450, on March 31, 2004

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By


Amelia Weintraub

Attorney Docket No. 411-000100US
Client Ref. No. G85

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Deh-Ming Chang, et al.

Application No.: 10/623,464

Filed: July 18, 2003

For: MODULATION OF INTERLEUKIN-10 BY DHEA

Examiner: Unassigned

Art Unit: 1645

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action on the merits per 37 CFR 1.97(b)(3). However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Paul Littlepage
Reg. No. 48,581

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)	Complete if Known	
	Application Number	10/623,464
	Filing Date	July 18, 2003
	First Named Inventor	Deh-Ming Chang
	Group Art Unit	1645
	Examiner Name	Unassigned
	Attorney Docket Number	411-000100US
Date Submitted	March 31, 2004	

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	01	4,366,241		Tom et al.	12-28-1982	
	02	4,376,110		David et al.	03-08-1983	
	03	4,517,288		Giegel et al.	05-14-1985	
	04	4,837,168		de Jaeger et al.	06-06-1989	
	05	6,552,010	B1	Schwartz et al.	04-22-2003	
	06	6,605,591	B1	Schwartz	08-12-2003	

FOREIGN PATENT DOCUMENTS


Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	07	WO	00/54763	A2	Genelabs Technologies, Inc.	09-21-2000		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	08	al-Janadi, et al., <u>J. Clin. Immunol.</u> , 1993(13):58-67.	
	09	Anaya, et al., <u>J. Rheuma.</u> , 2002, 29(9):1874-1876.	
	10	Araghi-Niknam, et al., <u>Proc. Soc. Exp. Biol. Med.</u> , 1997, 216:386-91.	
	11	Badou, et al., <u>J. Virology</u> , 2000, 74(22):10551-10562.	
	12	Bombardier, et al., <u>Arthritis Rheum.</u> , 1992, 35:630-40.	
	13	Chang, et al., <u>Arthritis Rheum.</u> , 2002, 46(11):2924-27.	
	14	Cortes, et al., <u>Blood</u> , 1995, 85(9):2516-2520.	
	15	Daynes, et al., <u>Eur. J. Immunol.</u> 1990, 20:793-802.	
	16	Ebeling, et al., <u>Lancet</u> , 1994 (343):1479-81.	
	17	Fayad, et al., <u>Blood</u> , 2001, 97(1):256-263.	
	18	Gordon, et al., <u>Cytokine</u> , 2001, 16(5):178-86.	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT 	Complete if Known	
	Application Number	10/623,464
	Filing Date	July 18, 2003
	First Named Inventor	Deh-Ming Chang
	Group Art Unit	1645
	Examiner Name	Unassigned
	Attorney Docket Number	411-000100US
Date Submitted	March 31, 2004	

19	Hagiwara, et al., <u>Arthritis Rheum.</u> , 1996, 39:379-385.	
20	Handwerger, et al., <u>Springer Semin. Immunopathol.</u> , 1994, 16:153-80.	
21	Houssiau, et al., <u>Lupus</u> , 1995, 4:393-395.	
22	Isomäki, et al., <u>Arthritis Rheum.</u> , 1996, 39(3):386-395.	
23	Labrie, et al., <u>Ann. N.Y. Acad. Sci.</u> , 1995, (774):16-28.	
24	Lacki, et al., <u>Clinical Rheumatology</u> , 1997, 16(3):275-278.	
25	Liang, et al., <u>Arthritis Rheum.</u> , 1989, 32:1107-18.	
26	Linker-Israeli, et al., <u>J. Immunol.</u> , 1991, 147:117-23.	
27	Llorente, et al., <u>Eur. Cytokine Netw.</u> , 1993, 4:421-30.	
28	Llorente, et al., <u>Arthritis Rheum.</u> , 1994, 37(11):1647-1655.	
29	Llorente, et al., <u>Arthritis Rheum.</u> , 2000, 43(8):1790-1800.	
30	Lucas, et al., <u>J. Clin. Invest.</u> , 1985, 75:2091-93.	
31	Mease, et al., <u>Arthritis Rheum.</u> , 2000, 43(Suppl. 1):S271.	
32	Melez, et al., <u>Arthritis Rheum.</u> , 1980, 23:41-7.	
33	Mund, et al., <u>JAMA</u> , 1963, 183:917-20.	
34	Nunnari, et al., <u>Ann. Intern. Med.</u> , 2003, 139(1):26-30.	
35	Park, et al., <u>Clin. Exp. Rheumatol.</u> , 1998, 16(3):283-8.	
36	Parker, <u>Endocrinol. Metab. Clin. North Am.</u> , 1991 20:401-21.	
37	Perrier, et al., <u>J. Rheumatol.</u> , 2000, 27:935-9.	
38	Petri, et al., <u>Arthritis Rheum.</u> , 2002 (46):1820-9.	
39	Petri, et al., <u>Rheumatology</u> , 2003:42(Suppl. 1):19.	
40	Petri, et al., <u>Arthritis Rheum.</u> , 1991, 34:1538-45.	
41	Richaud-Patin, et al., <u>Rev. Invest. Clin.</u> , 1995, 47:267-72.	
42	Roubinian, et al., <u>Arthritis Rheum.</u> , 1979, 22:1162-69.	
43	Straub, et al., <u>J. Clin. Endocrinol. Metab.</u> , 1998, 83:2012-17.	
44	Suzuki, et al., <u>Clin. Immunol. Immunopathol.</u> , 1991, 61:202-11.	
45	Tabata, et al., <u>Arch. Dermatol. Res.</u> , 1997, 289:410-14.	
46	Takemura, et al., <u>Virchows Archiv.</u> , 1994(424):459-64.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/623,464
	Filing Date	July 18, 2003
	First Named Inventor	Deh-Ming Chang
	Group Art Unit	1645
	Examiner Name	Unassigned
	Attorney Docket Number	411-000100US
	Date Submitted	March 31, 2004

	47	Tan, et al., <u>Arthritis Rheum.</u> , 1982, 25:1271-77.	
	48	van Vollenhoven, et al., <u>Arthritis Rheum.</u> , 1994(37):1305-10.	
	49	van Vollenhoven, et al., <u>Arthritis Rheum.</u> , 1995(38):1826-31.	
	50	Zietz, et al., <u>J. Rheumatol.</u> , 2000, 27:911-8.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.